First-in-human results prompt a biomarker-defined approach for CID-078.
ApexOnco Front Page
Recent articles
AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.
Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.
Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.
The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.
Enzomenib might be the most promising agent so far, on a cross-trial basis.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
